Breeze Meds vs MEDVi: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

52 providers verified independently·Independent research·How we rank →

MEDVi beats Breeze Meds overall, scoring 7.7/10 vs 7.3/10. MEDVi is more affordable at $179/mo vs $199/mo. Choose Breeze Meds for users who want to order compounded glp-1s month-by-month wit. Choose MEDVi for users who want a low entry price with oral and injectable co.

A side-by-side look at Breeze Meds and MEDVi to help you decide. We compare them on:

•Starting price per month
•Our overall score, out of 10
•Medication type, brand-name or compounded
•Whether they accept insurance
•Who each one is best for

Breeze Meds

#33 of 52

7.3/10

Compounded GLP-1 provider focused on fast shipping and a no-fuss enrollment process.

Visit Breeze Meds

Higher Rated

MEDVi

#20 of 52

7.7/10

MEDVi is a compounded GLP-1 telehealth platform offering both oral tablets and injectable semaglutide and tirzepatide, with micro-dosing options for side-effect-sensitive patients. $179/mo entry pricing, free shipping, and a streamlined intake, one of the broader compounded mixes among independent telehealth providers in 2026.

Visit MEDVi

Feature	Breeze Meds	MEDVi
Our Score	7.3/10	7.7/10
Starting Price	$199/mo	$179/mo
Medication Type	Compounded	Both
Insurance Accepted	No	No
Best For	Users who want to order compounded GLP-1s month-by-month with no subscription commitment	Users who want a low entry price with oral and injectable compounded options
Ranking	#33	#20
Get started	Visit Breeze Meds	Visit MEDVi

Pros & Cons Compared

Breeze Meds

Pros

+No subscription required, order on demand without recurring billing commitments
+Three formulation options: injectable semaglutide, oral semaglutide tablet, and oral tirzepatide tablet
+FSA/HSA eligible for those with health savings accounts
+Discreet packaging on all shipments

Cons

−Independent reviews are very limited and the company structure is unclear, so legitimacy is hard to verify. Ask for pharmacy details first; the no-subscription model at least keeps a first order low-commitment.
−Oral options at $299-399/mo cost significantly more than injectable alternatives. The $199 injectable semaglutide is the value pick unless tablets are a must.
−Not available in all 50 states; availability depends on provider licensure, so check your state early in the online visit.

MEDVi

Pros

+One of the few compounded providers offering both oral tablets and injectable semaglutide
+Micro-dosing options available, can start at sub-standard doses for patients concerned about side effects
+Sleek onboarding experience with clear progress tracking through their patient portal
+$179/mo is competitive for a platform with both oral and injectable compounded formulations

Cons

−No brand-name Wegovy or Zepbound on the platform (the 2026 expansion added branded Ozempic only)
−No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms; you can switch to injectable anytime at no extra fee if results lag

Our Verdict

MEDVi edges out Breeze Meds with a score of 7.7/10 vs 7.3/10. If budget is your priority, MEDVi starts at $179/mo compared to Breeze Meds's $199/mo. MEDVi offers both brand-name and compounded medications, giving you more flexibility. Choose Breeze Meds if you want: users who want to order compounded glp-1s month-by-month with no subscription commitment. Choose MEDVi if you want: users who want a low entry price with oral and injectable compounded options.

Still undecided? Editor's Featured Pick

Yucca Health

$146/mo · 7.7/10 · Compounded

If neither Breeze Meds nor MEDVi feels like the right fit, our featured pick across all 52 GLP-1 telehealth providers is Yucca Health. It is not the highest-scored provider in our full rankings. We feature it for its low-friction value: a flat $146/mo that stays the same at every dose.

Visit Yucca Health→Read our full Yucca Health review